CLL442X
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $153,356 | 6 | 0 |
| 2017 | $113.62 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $153,470 | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED INVESTIGATOR AND PATIENT BLIND PLACEBO CONTROLLED PARALLEL GROUP FIRST IN HUMAN AND PROOF OF CONCEPT STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF CLL442 IN PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA IN SITU SCCIS | Novartis Pharmaceuticals Corporation | $153,470 | 0 |
Top Doctors Receiving Payments for CLL442X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $153,470 | 10 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $153,470
Product Information
- Type Drug
- Total Payments $153,470
- Total Doctors 0
- Transactions 10
About CLL442X
CLL442X is a drug associated with $153,470 in payments to 0 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $153,356 was paid across 6 transactions to 0 doctors.
The most common payment nature for CLL442X is "Unspecified" ($153,470, 100.0% of total).
CLL442X is associated with 1 research study, including "A RANDOMIZED INVESTIGATOR AND PATIENT BLIND PLACEBO CONTROLLED PARALLEL GROUP FIRST IN HUMAN AND PROOF OF CONCEPT STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF CLL442 IN PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA IN SITU SCCIS" ($153,470).